title: Hepatotoxicity with combination of vemurafenib and ipilimumab.
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Margaret
authors.initials: M
authors.lastname: Callahan
authors.forename: Cyril
authors.initials: C
authors.lastname: Konto
authors.forename: Jedd
authors.initials: J
authors.lastname: Wolchok
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D007211:Indoles; D000074324:Ipilimumab; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf